KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Stewart ML, Tamayo P, Wilson AJ, Wang S, Chang YM, Kim JW, Khabele D, Shamji AF, Schreiber SL (2015) Cancer Res 75: 2897-906 Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM (2002) Obstet Gynecol 99: 3-10 Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM (2007) Gynecol Oncol 105: 625-9 Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM (2007) Cancer Biol Ther 6: 795-801 An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA (2012) Int J Clin Exp Pathol 5: 37-45 Changes in gene expression during progression of ovarian carcinoma. Tapper J, Kettunen E, El-Rifai W, Seppälä M, Andersson LC, Knuutila S (2001) Cancer Genet Cytogenet 128: 1-6 Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Fadare O, James S, Desouki MM, Khabele D (2013) Ann Diagn Pathol 17: 430-3 Masquerading as Sigmoid Adenocarcinoma: A Unique Presentation of High-Grade Serous Carcinoma Arising from Endometriosis. Johnson WR, Kensinger CD, Desai MA, Hawkins AT (2017) Am Surg 83: e316-317
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.